Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept ScienceDirect CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Cagrilintide and semaglutide act individually on both EI and EE a, Download Scientific Diagram Cagrilintide 5 mg